Platinum-resistant ovarian cancer (PROC)
Clinical trials for Platinum-resistant ovarian cancer (PROC) explained in plain language.
Never miss a new study
Get alerted when new Platinum-resistant ovarian cancer (PROC) trials appear
Sign up with your email to follow new studies for Platinum-resistant ovarian cancer (PROC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new drug tackle Hard-to-Treat gynecologic cancers?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called ARR-002 in adults with advanced or metastatic ovarian or endometrial cancer, including cases that have stopped responding to platinum-based chemotherapy. The main goals are to assess the drug's safety, tolerability,…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER (PROC)
Phase 1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug Rina-S shows promise in battling Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER (PROC)
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC